Okyo Pharma LTD (OKYO) SEC Filings — 2024
27 SEC filings for Okyo Pharma LTD (OKYO) in 2024.
Filings
- OKYO Pharma CEO to Speak at BTIG Ophthalmology Day — 6-K · Nov 26, 2024
- OKYO Pharma to Present at Ocular Surface Conference — 6-K · Oct 30, 2024
- OKYO Pharma Doses First Patient in OK-101 Phase 2 NCP Trial — 6-K · Oct 23, 2024
- OKYO Pharma Starts Phase 2 Trial for OK-101 — 6-K · Oct 16, 2024
- OKYO Pharma: Chairman's Entity Buys 50,000 Shares — 6-K · Sep 10, 2024
- OKYO Pharma: Chairman's associate buys 80,000 shares — 6-K · Sep 5, 2024
- OKYO Pharma Secures US Patent for Dry Eye Treatment — 6-K · Aug 27, 2024
- OKYO Pharma: Chairman's associate buys 50,000 shares — 6-K · Aug 23, 2024
- OKYO Pharma: Chairman's Entity Buys 35,000 Shares — 6-K · Aug 21, 2024
- OKYO Pharma to Participate in H.C. Wainwright Ophthalmology Conference — 6-K · Aug 15, 2024
- OKYO Pharma Ltd Files 20-F for FY Ending March 31, 2024 — 20-F · Aug 13, 2024
- OKYO Pharma Secures Key European Patent for Chemerin Analogs — 6-K · Aug 6, 2024
- OKYO Pharma to Start Phase 2 Trial for Neuropathic Corneal Pain — 6-K · Jul 11, 2024
- OKYO Pharma Ltd Files New Investor Presentation — 6-K · Jul 10, 2024
- OKYO Pharma to Present at May Investor Conferences — 6-K · May 8, 2024
- OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data — 6-K · Apr 30, 2024
- OKYO Pharma Reschedules KOL Event for OK-101 Phase 2 Trial Results — 6-K · Apr 9, 2024
- OKYO Pharma Ltd. Files 6-K with SEC — 6-K · Apr 4, 2024
- OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data — 6-K · Apr 2, 2024
- OKYO Pharma Ltd Reports Interim Results — 6-K · Mar 29, 2024
- OKYO Pharma's OK-101 Trial Shows Success in Dry Eye Disease — 6-K · Mar 22, 2024
- OKYO Pharma to Host KOL Event for OK-101 Phase 2 Data — 6-K · Mar 21, 2024
- OKYO Pharma to Release Dry Eye Trial Data March 22 — 6-K · Mar 20, 2024
- OKYO Pharma's OK-101 Cleared by FDA for Neuropathic Corneal Pain IND — 6-K · Feb 9, 2024
- OKYO Pharma Adds Top Ophthalmologists to Scientific Advisory Board — 6-K · Jan 31, 2024
- OKYO Pharma's OK-101 Hits Key Endpoints in Phase 2 Dry Eye Trial — 6-K · Jan 8, 2024
- OKYO Pharma to Present at Biotech Showcase, Seek Partnerships — 6-K · Jan 5, 2024